PORTLAND, Ore.--(BUSINESS WIRE)--Aug. 8, 2006--AVI BioPharma, Inc. (Nasdaq:AVII - News) today reported financial results for the three and six months ended June 30, 2006. The net loss for the second quarter of 2006 was $6.9 million, or $0.13 per share, compared with a net loss for the second quarter of 2005 of $4.9 million, or $0.11 per share. Results for the second quarter of 2006 include stock-based compensation expenses of $1.0 million upon adoption of SFAS 123R. Results for the second quarter of 2005 do not include SFAS 123R compensation expenses since the adoption occurred beginning January 1, 2006. Revenues for the 2006 second quarter were $19,000, down from $39,000 in the prior-year quarter and reflecting lower grant revenues, partially offset by higher research contract revenues.
